Noema Pharma AG closes Series B financing
Noema Pharma AG receives €104m in oversubscribed Series B financing round to advance its central nervous system pipeline.
ADVERTISEMENT
About Uta Mommert
This author has not written his bio yet.
But we are proud to say that Uta Mommert contributed 287 entries already.
Entries by Uta Mommert
Money for AI-powered drug discovery
Antiverse Ltd.’s AI identified eight antibodies with therapeutic potential for humans and raised €2.8m in funding for continued in-house development.
Upping sustainability in pharma packaging
How to make pharma packaging sustainable was one of the major discussion topics at PHARMAPACK 2023.
Novo Holdings invests into standardisation of LC-MS-based proteomics
Evosep APS has inked a $40m funding deal with Novo Holdings A/S that is aimed to advance standardised clinical LC-MS-based drug discovery and diagnostic multi-marker tests.
Collaboration to develop mRNA vaccine against betacoronaviruses
CEPI fights the betacoronaviruses by funding Ethris GmbH and DIOSynVax Ltd and their joint effort to advance their work on an mRNA vaccine.
First allogeneic cancer immunotherapy hits market
Atara Biotherapeutics Inc. and Pierre Fabre SA announced the approval of Tabelecleucel, a therapy for a rare and potentially fatal malignancy.
€72M from Novo´s REPAIR Impact Fund for Group B Streptococcus vaccines
MinervaX inks €72m financing deal with Novo Holdings REPAIR Impact Fund to develop a vaccine against Group B Streptococcus.
A ray of hope in leukaemia
A child with recurrent T-cell leukaemia was given base-edited T-cells in a world-first application of a base-edited cell therapy.
Step Pharma presents promising cancer treatment
Step Pharma intruduces promising data on the potential of a selective cancer treatment by inhibition of CTPS1 with their inhibitor STP938.
Partnering revitalized at the BioFit2022 – in Strasbourg and online
The partnering event BioFit2022 took place in Strasbourg, France on November 29th and 30th as well as online on December 7th and 8th. It reflected on challenging times in the pandemic, survivors’ of the economic threats, and adressed the preparation and perseverance needed to deal with challenges today and in the future. The bottom line: dynamic partnerships and more financing opportunities on the horizon.